Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to assess the efficacy of Manremyc® food supplement for reduce the incidence of SARS-CoV-2 infection in a high risk population, as healthcare workers.
Description: % of positive serology at the end of the study or positive PCR test in the course of routine clinical practice
Measure: Documented cumulative incidence of SARS-CoV-2 infection Time: up to 4 monthsDescription: Number of days Documented as sick leave for SARS-CoV-2
Measure: Documented sick leave for SARS-CoV-2 Time: up to 4 months (cumulative)Description: Number of days off work due to the quarantine imposed as a consequence to have acute respiratory symptoms, fever or infection documented by SARS-CoV-2
Measure: days off work due to the quarantine Time: up to 4 monthsDescription: Number of days in quarantine imposed by close contact outside the center with SARS-CoV-2 positive
Measure: Quarantine imposed by close contact outside the center with SARS-CoV-2 positive Time: up to 4 monthsDescription: Number of days of self-reported fever (≥38 ºC)
Measure: Fever Time: Up to 4 monthsDescription: Cumulative incidence of self-reported acute respiratory symptoms
Measure: Cumulative incidence of self-reported acute respiratory symptoms Time: up to 4 monthsDescription: Number of days of self-reported acute respiratory symptoms
Measure: Number of days of self-reported acute respiratory symptoms Time: up to 4 monthsDescription: Number of participants with pneumonia confirmed by X-ray
Measure: Incidence of pneumonia Time: up to 4 monthsDescription: Cumulative incidence of death from documented SARS-CoV-2 infection
Measure: Cumulative incidence of death from documented SARS-CoV-2 infection Time: Up to 4 monthsDescription: Cumulative incidence of admissions to intensive care unit for documented SARS-CoV-2 infection
Measure: Incidence of admission to ICU Time: Up to 4 monthsDescription: Number of days admitted to the ICU for documented SARS-CoV-2 infection
Measure: Days in IUC Time: Up to 4 monthsDescription: Cumulative incidence of need for mechanical ventilation due to documented SARS-CoV-2 infection
Measure: Incidence of mechanical ventilation Time: Up to 4 monthsDescription: Cumulative incidence of hospital admissions for documented SARS-CoV-2 infection
Measure: Incidence of hospital admissions Time: Up to 4 monthsDescription: Number of days of hospitalization for documented SARS-CoV-2 infection
Measure: Days of hospitalization Time: Up to 4 monthsDescription: Levels of IgG
Measure: Levels of IgG Time: Up to 4 monthsDescription: Levels of IgM
Measure: Levels of IgM Time: Up to 4 monthsDescription: Levels of SARS-CoV-2 antibodies at the end of the study period
Measure: Levels of SARS-CoV-2 antibodies at the end of the study period Time: Up to 4 monthsDescription: All adverse events reported by the subjects, both serious and non-serious, will be collected. All events related to a SARS-CoV-2 infection will be exempted from collection, as they will be collected as part of the associated symptoms
Measure: AEs Time: Up to 4 monthsDescription: All thoseAdverse Events that lead to hospitalization of the patient, that endanger his life or cause or may cause death.
Measure: SAEs Time: Up to 4 moths